Evidence map›Paper›PMID 16306548›Full record

Trial reportDiabetes care2005

Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.

Judith G Regensteiner, Timothy A Bauer, Jane E B Reusch

Registry-linked trialOpen access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes care, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01881828 (A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes), which is not on this map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01881828 phase3completedstarted 2013, after this paper: background citation

A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes

Ran2013Enrolled164Registered outcomes16Posted comparisons0ConditionsType 1 DiabetesArmsMetformin (glucophage), oral placebo
PMID 22540912PMID 15855566PMID 18777487PMID 12502670PMID 23175691PMID 19996308PMID 20393934PMID 14514594PMID 9737804PMID 9690199PMID 9669786PMID 8640398other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 87 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Rosiglitazone improves insulin resistance but does not improve exercise capacity in individuals with impaired glucose tolerance: A randomized clinical study.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2024
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Judith G RegensteinerDivision of Internal Medicine, Center for Women's Health Research, Box B-180, University of Colorado Health Sciences Center, 4200 E. 9th Ave., Denver, CO 80262, USA. judy.regensteiner@uchsc.edu
Timothy A Bauer
Jane E B Reusch
University of Colorado Health · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI CAMPBELL, THOMAS A · 1985 to 2008
$52.6M
NCRR NIH HHS M01 RR 00051
6 · The paper itself

Abstract

objectiveAlthough exercise is recommended as a cornerstone of treatment for type 2 diabetes, it is often poorly adopted by patients. We have noted that even in the absence of apparent cardiovascular disease, persons with type 2 diabetes have an impaired ability to carry out maximal exercise, and the impairment is correlated with insulin resistance and endothelial dysfunction. We hypothesized that administration of a thiazolidinedione (TZD) agent would improve exercise capacity in type 2 diabetes. RESEARCH DESIGN AND

methodsTwenty participants with uncomplicated type 2 diabetes were randomly assigned in a double-blind study to receive either 4 mg/day of rosiglitazone or matching placebo after baseline measurements to assess endothelial function (brachial artery diameter by brachial ultrasound), maximal oxygen consumption (VO(2max)), oxygen uptake (VO(2)) kinetics, and insulin sensitivity by hyperinsulinemic-euglycemic clamp. Measurements were reassessed after 4 months of treatment.

resultsParticipant groups did not differ at baseline in any measure. Rosiglitazone-treated participants (n = 10) had significantly improved VO(2max) (19.8 +/- 5.3 ml . kg(-1) . min(-1) before rosiglitazone vs. 21.2 +/- 5.1 ml . kg(-1) . min(-1) after rosiglitazone, P < 0.01), insulin sensitivity, and endothelial function. A change in VO(2max) correlated with improved insulin sensitivity measured by clamp (r = 0.68, P < 0.05) and with improved brachial artery diameter (r = 0.70, P < 0.05). Placebo-treated participants (n = 10) showed no changes in VO(2max) (19.4 +/- 5.2 ml . kg(-1) . min(-1) before rosiglitazone vs. 18.1 +/- 5.3 ml . kg(-1) . min(-1) after rosiglitazone, NS) or brachial artery diameter.

conclusionsThis is the first known report showing that a TZD improved exercise function in type 2 diabetes. Whether this is due to the observed improvements in insulin sensitivity and/or endothelial function or to another action of the TZD class requires further exploration.

Indexed as

ExerciseAdipose TissueAdultBlood GlucoseBody Mass IndexBrachial ArteryDiabetes Mellitus, Type 2Double-Blind MethodFastingGlucose Clamp TechniqueHumansHyperinsulinismHypoglycemic AgentsInsulinMiddle AgedOxygen ConsumptionBlood GlucoseHypoglycemic AgentsInsulinRosiglitazoneThiazolidinediones

Identifiers

PMID16306548
OpenAlexW2168968236

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.